Sevirumab

Modify Date: 2024-01-02 12:21:45

Sevirumab structure	Common Name	Sevirumab
	CAS Number	138660-96-5	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Sevirumab

Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2].

Name	Sevirumab

Description	Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> CMV
Target	EC50: 0.3 μg/mL (CMV)[1]
In Vitro	Sevirumab (MSL-109) 扰乱 gH/gL 同型二聚体，而不是取消二聚。Sevirumab 可以将二聚体在足够的距离上分开，以减少荧光共振能量转移 (FRET)，并最终阻止正常的 gH/gL 功能[2]。
References	[1]. Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994 May;24(1):17-26. [2]. Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8209-14.

No Any Chemical & Physical Properties

Sevirumab

Use of Sevirumab

Names

Sevirumab Biological Activity

Chemical & Physical Properties